Cancer Treatment News and Research

RSS

Physician describes ways to combat post-cancer pain

More and more people are surviving their cancer. Unfortunately, sometimes survival can come with pain. Although many people won't feel any pain after their cancer treatment, some may have chronic, bothersome pain.

23 Jun 2014

Telephone-based weight loss intervention is effective in breast cancer treatments

A series of simple telephone calls can make a profound difference in helping women to meet their treatment goals for breast cancer, according to a randomized trial of women who are also obese, published online today in Journal of Clinical Oncology by Dr. Pamela Goodwin of Mount Sinai Hospital and the Lunenfeld-Tanenbaum Research Institute.

20 Jun 2014

Scientists discover major breakthrough in cancer treatment

Scientists at the Sahlgrenska Academy, University of Gothenburg, have developed a new cancer treatment that has proved to be effective in mice. The treatment, which is presented in the prestigious scientific journal PNAS, is based on newly discovered properties of the so-called BET bromodomain inhibitors.

20 Jun 2014

Western Oncolytics closes $275,000 in seed funding

Western Oncolytics Ltd., a biotech company specializing in immuno-oncolytic cancer therapies, has closed $275,000 in seed funding. The proceeds are planned to set a path toward clinical trials and execute initial manufacturing for its novel virus-based cancer therapy, which delivers genes to guide the immune system to kill cancer cells.

18 Jun 2014

Trovagene enters into clinical collaboration with Dana-Farber Cancer Institute

Trovagene, Inc. today announced that it has entered into a clinical collaboration with Dana-Farber Cancer Institute to investigate the utility of quantitative urine-based mutation detection and the ability to monitor tumor mutation burden and treatment response over time in metastatic melanoma patients.

16 Jun 2014

Survivors of childhood cancers hospitalized more often many years after cancer treatment

Survivors of childhood cancers were hospitalized more often and for longer durations because of blood disorders and other problems, many years after cancer treatment was completed, compared with the general population, according to a study published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

13 Jun 2014

Paradigm shift in new, highly targeted leukaemia therapy

Australian researchers are zeroing in on a promising new approach to killing off cancer cells in patients with leukemia.

11 Jun 2014

New guidelines aim to improve delivery of prostate cancer survivorship care

New American Cancer Society Prostate Cancer Survivorship Care guidelines released today outline posttreatment clinical follow-up care for the myriad of long-term and late effects an estimated 2.8 million prostate cancer survivors in the United States may face.

11 Jun 2014

Celsion signs definitive asset purchase agreement to acquire EGEN

Celsion Corporation (Celsion) (NASDAQ: CLSN), an oncology drug development company, and EGEN, Inc. (EGEN), a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases, today announced the signing of a definitive asset purchase agreement in which Celsion will acquire substantially all of the assets of EGEN, including its Phase Ib DNA-based immunotherapy product candidate EGEN-001 and its therapeutic platform technologies, TheraPlas™ for delivery of DNA and mRNA, TheraSilence™ for delivery of RNA, and RAST™ for Cell Enabled Expression and Secretion of RNA.

10 Jun 2014

Inovio evaluates responses of immunotherapy product in treating HPV linked head and neck cancer

Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced it has initiated a phase I/IIa clinical trial to evaluate safety, immunogenicity and clinical responses of its immunotherapy product, INO-3112, in treating human papillomavirus (HPV)- associated head and neck cancer.

10 Jun 2014

MD Anderson study shows that needle biopsy underused in breast cancer patients

Needle biopsy, the standard of care radiological procedure for diagnosing breast cancer, is underused with too many patients undergoing the more invasive, excisional biopsy to detect their disease, according to research from The University of Texas MD Anderson Cancer Center.

10 Jun 2014

Mylan launches generic version of Bristol-Myers Squibb's Paraplatin Injection

Mylan Inc. today announced that it has launched Carboplatin Injection, 50 mg/5 ml, in multi-dose vials, which is the generic version of Bristol-Myers Squibb's Paraplatin® Injection.

9 Jun 2014

Actinium's Chairman to discuss role of alpha-particle radiopharmaceuticals at SNMMI Annual Meeting

Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced that Actinium's Clinical Advisory Board Chairman Joseph Jurcic, MD will participate in an upcoming panel discussion highlighting the role of Actinium's alpha-particle radiopharmaceuticals in the treatment of leukemia patients.

9 Jun 2014

Research roundup: Funding for safety-net hospitals; insurance competition

Safety-net hospitals rely on disproportionate-share hospital (DSH) payments to help cover uncompensated care costs and underpayments by Medicaid

9 Jun 2014

SAP collaborates with MolecularHealth and GATC to offer personalized cancer treatment

In the spirit of its mission to improve people's lives, SAP AG today announced that it intends to offer a personalized treatment option service, in collaboration with MolecularHealth and GATC Biotech, to qualified employees fighting cancer.

6 Jun 2014

MolecularHealth launches innovative oncology program for employers

MolecularHealth announced today the official launch of MolecularHealth COPE (Corporate Oncology Program for Employers), powered by its cancer treatment decision support offering, TreatmentMAP.

6 Jun 2014

Immune Design begins treatment in LV305 Phase 1 clinical trial for cancer

Immune Design, a clinical-stage immunotherapy company focused on the development of novel immune-based therapies for cancer and other chronic conditions, today announced treatment of the first patient in a Phase 1 clinical trial of LV305, an immuno-oncology investigational agent from the company's DCVexTM lentiviral vector platform.

5 Jun 2014

Gamma and neutron imaging safe and effective in simulations

Gamma and neutron imaging offer possible improvements over existing techniques such as X-ray or CT, but their safety is not yet fully understood.

5 Jun 2014

Bariatric surgery not only helps reduce weight, but lowers cancer risk among obese people

Weight loss surgery might have more value than simply helping morbidly obese people to shed unhealthy extra pounds.

5 Jun 2014

Synthetic peptide carrier delivers drugs through blood-brain barrier for cancer treatment

Researchers at Mayo Clinic have demonstrated in a mouse model that their recently developed synthetic peptide carrier is a potential delivery vehicle for brain cancer chemotherapy drugs and other neurological medications. The findings appear in PLOS ONE.

4 Jun 2014